NASDAQ:NOVN
Delisted
Novan, Inc. Stock News
$0.0941
+0 (+0%)
At Close: Nov 20, 2023
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022
09:05am, Thursday, 04'th Aug 2022
DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday
Applications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
05:15am, Monday, 25'th Jul 2022 GlobeNewswire Inc.
Basel, July 25, 2022 – Sandoz, a global leader in generic and biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its biologics license application (BLA
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
05:15am, Thursday, 21'st Jul 2022 GlobeNewswire Inc.
Basel, July 21, 2022 – Sandoz, a global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) has accepted for review its Supplemental Biologics
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022
02:04pm, Tuesday, 19'th Jul 2022 Benzinga
Upgrades
According to B of A Securities, the prior rating for Plains GP Holdings LP (NASDAQ:PAGP) was changed from Underperform to Neutral. For the first quarter, Plains GP Holdings had an EPS of $0.3
Novan Satisfies $16.5 Million Outstanding Promissory Note
12:30pm, Tuesday, 19'th Jul 2022 GlobeNewswire Inc.
– Novan and Evening Post Group enter into a loan payoff and termination agreement, fully satisfying the promissory note and all related obligations –
Novartis erzielt eine anhaltend starke Dynamik der wichtigsten Wachstumsmarken sowie Fortschritte bei strategischen Initiativen und bestätigt die Konzernprognose für das Geschäftsjahr 2022
05:00am, Tuesday, 19'th Jul 2022 GlobeNewswire Inc.
Ad-hoc-Mitteilung gemäss Art. 53 KR
Novartis continue le fort élan des principales marques de croissance, progresse dans ses initiatives stratégiques et confirme les prévisions de l’exercice 2022 pour le Groupe
05:00am, Tuesday, 19'th Jul 2022 GlobeNewswire Inc.
Annonce événementielle au sens de l’art. 53 RC
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
05:00am, Tuesday, 19'th Jul 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR
Beat The Bear With 3 Tools: Dividends, Dividends And Dividends
12:28pm, Sunday, 10'th Jul 2022 Investing.com
New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy
08:00am, Thursday, 30'th Jun 2022 GlobeNewswire Inc.
Basel, June 30, 2022 — Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) as a first-line tre
Novartis receives positive CHMP opinion for Scemblix®, a novel treatment for adult patients with chronic myeloid leukemia
11:13am, Friday, 24'th Jun 2022 GlobeNewswire Inc.
Basel, June 24, 2022 — Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended g
Is Vanguard International Dividend Appreciation ETF (VIGI) a Strong ETF Right Now?
10:20am, Thursday, 23'rd Jun 2022 Zacks Investment Research
Smart Beta ETF report for VIGI
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments
12:01am, Thursday, 23'rd Jun 2022 GlobeNewswire Inc.
Basel, June 23, 2022 — Novartis endorses the Kigali Declaration on neglected tropical diseases (NTDs) and announces a five-year financial commitment of USD 250 million to the fight against NTDs and
Novartis Tafinlar + Mekinist receives FDA approval for first tumor-agnostic indication for BRAF V600E solid tumors
11:12pm, Wednesday, 22'nd Jun 2022 GlobeNewswire Inc.
Basel, June 23, 2022 — Novartis today announced the US Food and Drug Administration (FDA) granted accelerated approval for Tafinlar® (dabrafenib) + Mekinist® (trametinib) for the treatment of adul
Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
07:17pm, Tuesday, 21'st Jun 2022 GlobeNewswire Inc.
Ad hoc announcement pursuant to Art. 53 LR
